CY1110350T1 - ΣΤΟΧΕΥΜΕΝΗ ΕΝΔΟΚΥΤΤΑΡΙΚΗ ΜΕΤΑΦΟΡΑ ΕΝΩΣΕΩΝ ΜΕ ΠΡΩΤΕΪΝΗ ΘΕΡΜΙΚΟΥ ΣΟΚ 70 kD - Google Patents

ΣΤΟΧΕΥΜΕΝΗ ΕΝΔΟΚΥΤΤΑΡΙΚΗ ΜΕΤΑΦΟΡΑ ΕΝΩΣΕΩΝ ΜΕ ΠΡΩΤΕΪΝΗ ΘΕΡΜΙΚΟΥ ΣΟΚ 70 kD

Info

Publication number
CY1110350T1
CY1110350T1 CY20091100975T CY091100975T CY1110350T1 CY 1110350 T1 CY1110350 T1 CY 1110350T1 CY 20091100975 T CY20091100975 T CY 20091100975T CY 091100975 T CY091100975 T CY 091100975T CY 1110350 T1 CY1110350 T1 CY 1110350T1
Authority
CY
Cyprus
Prior art keywords
targeted
compounds
hsp70
intercellular transport
fragment
Prior art date
Application number
CY20091100975T
Other languages
English (en)
Inventor
Sheri M Fujihara
Steven G Nadler
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1110350T1 publication Critical patent/CY1110350T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει φορέα για μεταφορά μορίων με βιολογική λειτουργία σε τμήματα κυττάρων και πυρήνα. Ο φορέας που ανακοινώνεται είναι πρωτεΐνη θερμικού σοκ 70 ("Hsp70"), ή θραύσμα της Hsp70 όπως περιγράφεται στο παρόν, ως μέσο για κατευθυνόμενη, μη επεμβατική μεταφορά μορίων, όπως πρωτεΐνες, πεπτίδια ή DNA, που μπορούν να τροποποιήσουν τη γονιδιακή έκφραση. Η παρούσα εφεύρεση περιλαμβάνει επίσης χρήση της Hsp70, ή θραύσματος αυτής, για τροποποίηση κυτταρικής δραστηριότητας, κατά προτίμηση για τροποποίηση δραστηριότητας του πυρήνα σε κύτταρο ή κύτταρα.
CY20091100975T 1998-11-24 2009-09-21 ΣΤΟΧΕΥΜΕΝΗ ΕΝΔΟΚΥΤΤΑΡΙΚΗ ΜΕΤΑΦΟΡΑ ΕΝΩΣΕΩΝ ΜΕ ΠΡΩΤΕΪΝΗ ΘΕΡΜΙΚΟΥ ΣΟΚ 70 kD CY1110350T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10987298P 1998-11-24 1998-11-24
EP99960422A EP1133517B1 (en) 1998-11-24 1999-11-17 INTRANUCLEAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN

Publications (1)

Publication Number Publication Date
CY1110350T1 true CY1110350T1 (el) 2015-04-29

Family

ID=22330008

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100975T CY1110350T1 (el) 1998-11-24 2009-09-21 ΣΤΟΧΕΥΜΕΝΗ ΕΝΔΟΚΥΤΤΑΡΙΚΗ ΜΕΤΑΦΟΡΑ ΕΝΩΣΕΩΝ ΜΕ ΠΡΩΤΕΪΝΗ ΘΕΡΜΙΚΟΥ ΣΟΚ 70 kD

Country Status (10)

Country Link
EP (1) EP1133517B1 (el)
JP (1) JP4892132B2 (el)
AU (1) AU760081B2 (el)
CA (1) CA2352286C (el)
CY (1) CY1110350T1 (el)
DE (1) DE69941156D1 (el)
DK (1) DK1133517T3 (el)
ES (1) ES2327986T3 (el)
PT (1) PT1133517E (el)
WO (1) WO2000031113A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022656A2 (en) * 2000-09-13 2002-03-21 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
AU2002323845A1 (en) * 2002-04-02 2003-10-13 "Asgl-Farmatsevticheskie Innovatsii", Zakrytoe Aktsionernoe Obschestvo Recombinant chimeric protein for the target delivery of dna to eukariotic target cells
US7575738B2 (en) * 2004-08-13 2009-08-18 General Electric Company Heat shock protein as a targeting agent for endothelium-specific in vivo transduction
US8071533B2 (en) 2006-03-20 2011-12-06 University Of Medicine And Dentistry Of New Jersey Compositions and methods for modulating store-operated calcium entry
EP2195333A1 (en) * 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
DK2643468T3 (en) * 2010-11-22 2018-09-24 Amicus Therapeutics Inc Hitherto UNKNOWN SIGNAL SEQUENCES TO IMPROVE EXPRESSION AND SECRETARY OF RECOMBINANT ENZYMES AND OTHER PROTEINS
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP4043493A1 (en) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
US20180066241A1 (en) 2015-03-31 2018-03-08 Universite Pierre Et Marie Curie (Paris 6) Pro-apoptotic set and pp2a peptides
JP7026509B2 (ja) 2015-06-24 2022-02-28 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体およびフラグメント
JP2019509993A (ja) 2016-02-12 2019-04-11 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ（ｂ７ｈ５）抗体
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
BR112021006829A2 (pt) 2018-10-10 2021-07-20 Amicus Therapeutics, Inc. composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT700445E (pt) * 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
AU736318B2 (en) * 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins

Also Published As

Publication number Publication date
WO2000031113A1 (en) 2000-06-02
ES2327986T3 (es) 2009-11-05
JP2002530426A (ja) 2002-09-17
AU760081B2 (en) 2003-05-08
DK1133517T3 (da) 2009-11-23
CA2352286C (en) 2011-07-12
DE69941156D1 (de) 2009-09-03
CA2352286A1 (en) 2000-06-02
PT1133517E (pt) 2009-08-12
AU1731400A (en) 2000-06-13
EP1133517B1 (en) 2009-07-22
EP1133517A1 (en) 2001-09-19
EP1133517A4 (en) 2003-01-08
JP4892132B2 (ja) 2012-03-07

Similar Documents

Publication Publication Date Title
CY1110350T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΕΝΔΟΚΥΤΤΑΡΙΚΗ ΜΕΤΑΦΟΡΑ ΕΝΩΣΕΩΝ ΜΕ ΠΡΩΤΕΪΝΗ ΘΕΡΜΙΚΟΥ ΣΟΚ 70 kD
CY1105842T1 (el) Τροποποιημενες v πρωτεϊνες ιου ιλαρας
CY1122704T1 (el) Τροποποιημενα ολιγονουκλεοτιδια για αναστολη τελομερασης
BR0110610A (pt) Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
CY1109744T1 (el) Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων
AU9254801A (en) Methods for treating cell proliferative disorders and viral infections
DE69637147D1 (de) Transportproteine und deren verwendungen
CY1113731T1 (el) Μεθοδοι για δημιουργια παρασκευασματων κομιστων ανασυνδυασμενου aav υψηλου τιτλου απαλλαγμενων απο βοηθητικο ιο
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69838483D1 (de) Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
FR05C0020I2 (fr) Anticorps anti-VEGF
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
ATE476664T1 (de) Anti-vegf antikörper
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
Burdon Heat shock proteins in relation to medicine
CY1108603T1 (el) Συστηματα πρωτεϊνων μεταφορας λιπιδιων και η καλλυντικη δερματολογικη εφαρμογη τους
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
CY1112236T1 (el) Πεπτιδια που ειναι σε θεση να αναστελλουν την αλληλεπιδραση μεταξυ των πρεσενιλινων και του βητα-αμυλοειδους πεπτιδιου ή του προδρομου
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
DK1082423T3 (da) Cyclin E2-gener og -proteiner
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
CY1108619T1 (el) Πρωτεϊνη σπονδυλωτων patched-2
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung